An Elderly Patient Developed Ulcerative Colitis after SARS-CoV-2 mRNA Vaccination : A Case Report and Review of the Literature
An 86-year-old man presented to our hospital with symptoms of diarrhea and bloody stool, which had manifested two weeks after receiving his third severe acute respiratory syndrome coronavirus 2 mRNA vaccination. Colonoscopy revealed diffuse, rough-surfaced mucosa extending from the ascending colon to the rectum. Despite attempting probiotic treatment, the patient's condition did not improve, leading to admission. Endoscopic findings at admission worsened. Based on endoscopic and histopathological findings, the patient was diagnosed with ulcerative colitis. Corticosteroids and 5-aminosalicylic acid were administered, and the clinical symptoms improved. Subsequently, the disease worsened during steroid tapering, and filgotinib was added, leading to steroid-free remission.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 63(2024), 6 vom: 15. März, Seite 809-814 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shimada, Takahito [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse event |
|---|
| Anmerkungen: |
Date Completed 19.03.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.2891-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366624946 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366624946 | ||
| 003 | DE-627 | ||
| 005 | 20240425232635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.2891-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM366624946 | ||
| 035 | |a (NLM)38171875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shimada, Takahito |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Elderly Patient Developed Ulcerative Colitis after SARS-CoV-2 mRNA Vaccination |b A Case Report and Review of the Literature |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a An 86-year-old man presented to our hospital with symptoms of diarrhea and bloody stool, which had manifested two weeks after receiving his third severe acute respiratory syndrome coronavirus 2 mRNA vaccination. Colonoscopy revealed diffuse, rough-surfaced mucosa extending from the ascending colon to the rectum. Despite attempting probiotic treatment, the patient's condition did not improve, leading to admission. Endoscopic findings at admission worsened. Based on endoscopic and histopathological findings, the patient was diagnosed with ulcerative colitis. Corticosteroids and 5-aminosalicylic acid were administered, and the clinical symptoms improved. Subsequently, the disease worsened during steroid tapering, and filgotinib was added, leading to steroid-free remission | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 mRNA vaccine | |
| 650 | 4 | |a adverse event | |
| 650 | 4 | |a elderly patient | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a ulcerative colitis | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Takada, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Baba, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Iwashita, Masahide |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Takao |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Teruo |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Masahito |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 63(2024), 6 vom: 15. März, Seite 809-814 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2024 |g number:6 |g day:15 |g month:03 |g pages:809-814 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.2891-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2024 |e 6 |b 15 |c 03 |h 809-814 | ||